On April 7, 2021 Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, reported that an abstract will be included in the upcoming 2021 American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held virtually from April 10-15, 2021 (Press release, Cancer Advances, APR 7, 2021, View Source [SID1234577681]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract is entitled, "Vaccination with Polyclonal Antibody Stimulator (PAS) prevents pancreatic carcinogenesis in the KRAS mouse model" and is available at the AACR (Free AACR Whitepaper) meeting website at View Source!/9325/presentation/1168.
PAS is a cancer vaccine that induces antibodies to gastrin, a known stimulator of certain pancreatic cancers. Using a KRAS mouse model, the researchers measured the impact of PAS vaccine on pancreatic PanIN lesions, inflammation, and fibrosis. Compared to a control group, the PAS vaccine slowed progression of PanIN lesions and rendered the tumor microenvironment less carcinogenic.
Details of the abstract are below:
Abstract Title: Vaccination with Polyclonal Antibody Stimulator (PAS) prevents pancreatic carcinogenesis in the KRAS mouse model
Abstract Number: 109
Date: April 10-15, 2021